Macrozit (Azithromycin)

Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation step of peptide chain elongation. This action halts bacterial growth, producing a bacteriostatic effect against susceptible organisms while allowing the immune system to clear the infection.

The dosage of Macrozit is individualized by the prescriber according to the infection being treated, patient age, weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should determine the appropriate regimen.

Safety data for azithromycin in pregnancy are limited, and the drug should be used only when clearly needed after a risk‑benefit assessment by the treating physician. Breastfeeding mothers should consult their doctor, as azithromycin does pass into breast milk in small amounts.

To request Macrozit, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older macrolides such as erythromycin, azithromycin (Macrozit) has a longer half‑life, allowing once‑daily dosing and shorter treatment courses. It also tends to cause fewer gastrointestinal side effects and has a broader spectrum against atypical pathogens, making it a preferred option for many community‑acquired infections.

Macrozit should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability throughout its shelf life.

Macrozit is formulated for oral administration. It is taken with or without food, according to the prescribing information. The tablet (or capsule) should be swallowed whole with a glass of water; it should not be crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include QT interval prolongation leading to potentially life‑threatening arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be monitored for cardiac symptoms, rash, or persistent diarrhea, and medical attention sought promptly if these occur.

Macrozit should be avoided in individuals with known hypersensitivity to azithromycin or other macrolides, patients with a history of significant QT prolongation or ventricular arrhythmias, and those taking medications that strongly interact and cannot be safely managed. The prescriber will assess suitability for each patient.